If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.
Menu closed
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Cialis ® (tadalafil)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Cialis Summary of Product Characteristics (SmPC)
Cialis (tadalafil): Effect of skipping dose
Clinical trials of tadalafil for the once daily treatment of ED and/or signs and symptoms of BPH did not study the effect of skipping doses.
Effect
of skipping dose(s)
Tadalafil
dosed once daily has been studied in clinical trials for the
treatment of erectile
dysfunction
(ED), the signs and symptoms of benign prostatic hyperplasia (BPH),
and both ED and signs and symptoms of BPH. Once daily dosing allows
the achievement of steady state plasma concentration and clinical
efficacy was assessed following daily dosing (Cialis SmPC).
The
impact of a missed day of therapy has not been studied, but impact on
efficacy is likely to vary by patient. Some patients may notice
reduced efficacy from missing a single dose, while others may not
(Data on file).
REFERENCES
CIALIS
EU Summary of Product Characteristics [SmPC], Utrecht, The
Netherlands: Eli Lilly Nederland B.V.
Data
on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review:November 11, 2019
Was this answer helpful to you?
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com